ACU NUCLEAR SALT REACTOR: Tackling water & energy issues while advancing cancer treatment
Earlier this week, Abilene Christian University revealed a partnership with Texas Tech University and Natura Resources to deploy Natura's molten salt reactor (MSR). The goal of this collaboration is to combine MSR technology with water desalination and energy production systems, tackling the energy and water challenges faced by Texas.
New project will use ACU salt reactor to 'address Texas' critical energy and water needs'
ACU's plans for the Natura MSR-1, a liquid-fueled molten salt reactor, began several years ago. In 2022, they initiated the application process to gain approval for a molten salt research reactor. Currently, the reactor is still under construction at ACU's NEXT Lab and will be used for experiments aimed at advancing technology and medicine.
Director of ACU's NEXT Lab, Dr. Rusty Towell, shared how this reactor can also produce clean water while producing electricity.
'If you have dirty water to clean it, just needs energy. You can, of course, boil it off,' Towell explained. 'We can actually use the waste heat from water reactors, the leftover heat that's normally just rejected to the air. We can use that to clean water. So while we produce electricity, we can also produce clean water.'
ACU conducts AI research: Exploring benefits, challenges with support from Google grant
While water purification is important, especially here in Texas with our water supplies, this lab also has another purpose: utilizing radioactive isotopes for medical research to fight cancer. Towell explained how radioisotopes produced by the reactor can be used to specifically target and rapidly eliminate cancer cells.
'Those radioisotopes are produced basically in the core of stars and the core of nuclear reactors, but they only last for a few hours or days, maybe,' Towell shared. 'So how do you get them from those locations where they're made in the doctor's hands? This technology will allow us to do that. We're working on producing the raw materials that doctors need for these new treatments.'
The research reactor is one of only two reactors of its kind in the nation.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
World's Largest Free Iceberg Drifted for Decades—Now It's Cracking
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The world's largest iceberg is shedding large chunks of ice in the South Atlantic Ocean nearly 40 years since it first broke off from Antarctica's Filchner Ice Shelf. An image from NASA's Aqua satellite has shown new ice chunks near South Georgia that have broken off the iceberg named A-23A as it drifts in the southern part of the South Atlantic Ocean, around 1,500 miles north of its birthplace, according to a statement from NASA. Scientists have been closely monitoring A-23A due to concerns that it may collide with South Georgia, the largest of nine remote islands that form the South Georgia and South Sandwich Islands, "potentially threatening a delicate ecosystem which is home to penguins and seals," the National Oceanic and Atmospheric Administration (NOAA) noted in January. Two of the new ice chunks were large enough to be named and monitored by the U.S. National Ice Center (USNIC). Aqua's MODIS (Moderate Resolution Imaging Spectroradiometer) was able to capture this natural-color satellite image of A-23A and the new icebergs on July 22 following a break in the clouds and lengthening daylight hours in Antarctica. A NASA satellite image captured on July 22 showing chunks of ice near that have been shed from A-23A, the world's largest iceberg, near South Georgia. A NASA satellite image captured on July 22 showing chunks of ice near that have been shed from A-23A, the world's largest iceberg, near South Georgia. NASA Earth Observatory Around this time, the surface of A-23A spanned around 969 square miles. The new pieces, name A-23D and A-23E, were measured to be around 62 and 28 square miles, respectively, NASA said. The new ice pieces were first identified by Jan Lieser of Australia's Bureau of Meteorology using NovaSAR-1 radar data, before they were later confirmed by USNIC analyst Britney Fajardo via radar images from the European Space Agency's Sentinel-1 mission on July 15. "Radar satellites can take images of the Earth at polar night and through all weather conditions, including heavy clouds and even smoke," Lieser said in a statement. Back in January this year, A-23A was found to be slowly drifting northeast in the Southern Ocean, according to images captured by NOAA's GOES East satellite. As of January 16, the iceberg was reported to have an area that's roughly the size of Rhode Island, the USNIC said. From the start of March, A-23A has sat lodged on the Filchner Ice Shelf around South Georgia. "Icebergs that make it this far north are increasingly at the mercy of warm water, waves, and seasonal weather—factors that contribute to a berg's ultimate demise," NASA explained. By late May, A-23A split off into thousands of smaller chunks after colliding with an Antarctic island and continued drifting toward the eastern side of South Georgia. The iceberg followed the same currents that the massive A-68A iceberg rode in late 2020. "The austral winter journey continued to inflict damage on A-23A, which shed even more ice from its sides," NASA said. Despite the edges lost, A-23A is still the largest iceberg currently drifting freely in any of the world's oceans. Only D-15A is bigger, which lies grounded in the Amery Sea off east Antarctica, according to the space agency. Scientists expect more calving from the remainder of A-23A as it moves further north, NASA said, with extended daylight hours taking place in this part of the South Atlantic. Do you have a tip on a science story that Newsweek should be covering? Do you have a question about climate change? Let us know via science@
Newsweek
2 hours ago
- Newsweek
Weight Loss Drugs Like Ozempic Could Have Additional Health Benefit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Could diabetes and weight loss drugs like Ozempic (semaglutide) also protect the brain from stroke damage—or even help prevent strokes entirely? Three new studies suggest they might, with the potential of GLP-1 receptor agonists—such as Ozempic—extending beyond just blood sugar regulation and weight loss. According to a May 2024 KFF Health Tracking Poll, approximately one in eight U.S. adults (12 percent) report having used a GLP-1 agonist. Usage rates are notably higher among individuals with chronic health conditions: 43 percent of adults with diabetes, 25 percent with heart disease, and 22 percent of those who have been diagnosed as overweight or obese in the past five years have taken one of these medication. Now, emerging research suggests they may also offer significant neurological benefits. A stock image of woman injecting a Semaglutide Pen in her stomach. A stock image of woman injecting a Semaglutide Pen in her stomach. JNemchinova/iStock / Getty Images Plus Lower Stroke Mortality in Ozempic Users The first study, led by researchers at the University of Wisconsin-Madison, analyzed stroke outcomes among patients taking Ozempic. The team compared data from two large sources: the University of Wisconsin's health system and a global health collaborative. Among more than two million stroke patients from the global dataset, those on Ozempic were found to have a dramatically lower initial death rate—just 5.26 percent compared to 21.61 percent for non-users. Long-term survival rates also favored Ozempic users, with a 77.5 percent survival rate versus 30.95 percent for those not on the drug. The university's own data mirrored this trend: stroke mortality among Ozempic users was less than 5 percent, compared to more than 26 percent in non-users. Could Ozempic Reduce the Risk of Stroke? A second study, also from the University of Wisconsin-Madison, looked at whether Ozempic could lower the chance of experiencing a stroke in the first place. Researchers analyzed emergency department records nationwide, identifying individuals likely using Ozempic and comparing their stroke incidence rates. The study found that potential Ozempic users had significantly lower odds of suffering a stroke. The research team now hopes to confirm these findings using pharmacy records, which would more precisely track who is prescribed the drug. Brain Bleed Protection and Cognitive Benefits The final study, conducted by the University of Texas Medical Branch in Galveston, extended the investigation to brain hemorrhages—both spontaneous bleeds and those caused by aneurysms. The researchers examined the health record of patients who had experienced a stroke or hemorrhage for up to two years after the event in question. Their analysis indicated that GLP-1 agonists were associated with reduced risks of cognitive decline, seizures, repeat hemorrhages and death. "This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," paper author and neurosurgeon Dr. Matias Costa said in a statement. A Promising Frontier for GLP-1 Drugs Dr. Ahmed Elbayomy, a research fellow in neurological surgery at the University of Wisconsin-Madison and lead author on two of the studies said in a statement: "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding." As use of semaglutide-based drugs like Ozempic and Wegovy continues to expand, the possibility that they might also protect the brain could usher in a new era of neurological prevention—offering more than just metabolic benefits. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 agonists? Let us know via health@
Fox News
a day ago
- Fox News
Needle-free vaccine method delivers antibodies through dental floss in early study
Dental floss could eventually do much more than improve oral hygiene. A new study led by Texas Tech University and the University of North Carolina suggests that the thin filament could eventually double as a vaccine mechanism. In animal models, the researchers showed that dental floss can effectively release vaccines through the tissue between the teeth and gums, according to a press release. In the study, the flossing technique triggered the production of antibodies in "mucosal surfaces," such as the lining of the nose and lungs, the release stated. The findings were published in the journal Nature Biomedical Engineering. "Mucosal surfaces are important, because they are a source of entry for pathogens, such as influenza and COVID," said co-author Harvinder Singh Gill, professor of chemical and biomolecular engineering at North Carolina State University, in the release. With the traditional method of injecting vaccines, the antibodies are primarily produced in the bloodstream, he noted. "But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces," said Gill. "This improves the body's ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body." The vaccine enters through the "junctional epithelium," which is a thin layer of tissue in the deep pocket between the tooth and the gum. This tissue doesn't have the same barrier as other tissue linings, which means it can release immune cells into the body. In the study, the researchers added a peptide flu vaccine to unwaxed dental floss before flossing the teeth of lab mice, according to the release. Next, they compared the effectiveness of the floss-delivered vaccine to techniques that delivered it nasally or orally. "It would be easy to administer, and it addresses concerns many people have about being vaccinated with needles." "We found that applying vaccine via the junctional epithelium produces a far superior antibody response on mucosal surfaces than the current gold standard for vaccinating via the oral cavity, which involves placing vaccine under the tongue," said first author Rohan Ingrole, a Ph.D. student at Texas Tech University. "The flossing technique also provides comparable protection against the flu virus as compared to the vaccine being given via the nasal epithelium." In addition to flu, the test was repeated for three other vaccine types: proteins, inactivated viruses and mRNA. For all types, the flossing technique produced "robust antibody responses in the bloodstream and across mucosal surfaces," the release stated. Next, the research team aims to test the effectiveness of vaccine delivery to the epithelial junction in humans through the use of floss picks, which are easier to hold. "It would be easy to administer, and it addresses concerns many people have about being vaccinated with needles," Gill said. "And we think this technique should be comparable in price to other vaccine delivery techniques." Hua Wang, assistant professor of materials science and engineering at the University of Illinois' Grainger College of Engineering, was not involved in the study but shared his reaction to the findings. "This study presents a promising floss-based vaccination method that can avoid needle injection or any potentially painful procedure," he told Fox News Digital. "The authors demonstrated that vaccine components in the floss coating can penetrate the junctional epithelium in gingival sulcus and reach the underlying tissues, leading to systemic antibody responses." The floss-based vaccination method could help to improve patient compliance if it goes through the full evaluation process, he noted. There are some limitations and drawbacks associated with floss-based vaccines, the researchers acknowledged. Babies and toddlers who don't have teeth yet wouldn't be candidates for the technique, for example. "In addition, we would need to know more about how or whether this approach would work for people who have gum disease or other oral infections," Gill added. Wang agreed that many questions remain to be answered about this experimental vaccination method. "In addition to the unclear impact of gingival tissue infection on vaccination, the local and systemic side effects of this vaccination method remain to be understood," he told Fox News Digital. "For example, vaccination at the gingival tissue may initiate local inflammation that eventually induces undesirable side effects." It's also not yet clear what exact path the vaccine components follow when traveling from the tooth site to the tissues or how the immune responses are generated, Wang noted. For more Health articles, visit "Lastly, from the translation perspective, the efficacy of floss-based vaccines would need to be comparable to conventional needle-based vaccines." The study was funded by the National Institutes of Health (NIH) and by funds from the Whitacre Endowed Chair in Science and Engineering at Texas Tech University.
